Q4 2024 Arcutis Biotherapeutics Inc Earnings Call Transcript

Feb 25, 2025 / 09:30 PM GMT

Release Date Price: $12.2 (-1.53%)

Transcript 10-K8-K

Key Points

Positve

Arcutis Biotherapeutics Inc (ARQT) reported strong revenue growth with $71 million in Q4 2024, primarily driven by the Zari franchise.
The company achieved a 471% year-over-year growth in product sales, indicating robust market demand.
Arcutis Biotherapeutics Inc (ARQT) has secured broad access to commercially insured patients and is making progress in gaining Medicare and Medicaid coverage.
The company is expanding its product portfolio with anticipated approvals for new indications, including scalp and body psoriasis.
Arcutis Biotherapeutics Inc (ARQT) is well-capitalized with $228.6 million in cash and marketable securities, providing financial stability and flexibility.

Negative

The company faces typical Q1 gross-to-net fluctuations due to deductible resets and insurance plan changes, which may impact revenue.
There is a potential risk of cannibalization between the foam and cream formulations, although the company believes this is unlikely.
Arcutis Biotherapeutics Inc (ARQT) is still in the early stages of its growth, indicating that significant market penetration is yet to be achieved.
The company is facing ongoing intellectual property lawsuits, which could pose risks to its product exclusivity.
Despite strong revenue growth, the company does not expect to reach cash break-even until 2026, indicating ongoing financial challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ARQT.OQ - Arcutis Biotherapeutics Inc
Q4 2024 Arcutis Biotherapeutics Inc Earnings Call
Feb 25, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to Arcadis Biotherapeutics 2024 4th quarter and full year financial results conference call. At this time, all participants on the list and only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automatic message advising you, your hand is raised.

Please be advised after today's conference is being recorded.

I will hand the call over to Lattavarain, Vice President of finance and corporate controller. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.